FP-025 is under clinical development by Foresee Pharmaceuticals and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FP-025’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FP-025 is under development for the treatment of house dust mite (HDM)-allergic asthma, chronic obstructive pulmonary disease (COPD) and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through oral route. The therapeutic candidate is being developed based on stabilized injectable formulation (SIF) platform technology. It acts by selectively targeting MMP-12 enzyme. It was also under development for the treatment of acute lung injury, non-alcoholic steatohepatitis and wound healing.
It was under development for the treatment of covid 19 with associated acute respiratory distress syndrome (ARDS).
Foresee Pharmaceuticals overview
Foresee Pharmaceuticals (FP) is a clinical-stage pharmaceutical company. It focuses on developing drugs for unmet medical needs. The company’s product portfolio comprises FP-001, for prostate cancer, FP-002, for acromegaly and carcinoid tumors, FP-025, for asthma and chronic obstructive pulmonary disease, FP-020, for Alport syndrome and FP-008, for diabetic retinopathy. It harnesses the stabilized injectable formulation (SIF) platform technology to develop controlled release drug delivery systems for peptides, small molecules and proteins. The company works in collaboration with ScinoPharm and Pierre Fabre to research and develop its product portfolio. It has operational presence in Taiwan and the US. FP is headquartered in Taipei, Taiwan.
For a complete picture of FP-025’s drug-specific PTSR and LoA scores, buy the report here.